Treatments for CKD in People Living with T2DM Findings from systematic reviews and meta-analyses indicate that improved renal outcomes can be achieved through obesity management [8], intensive glycemic control using glucose-lowering medications [9], and anti-hypertension drugs [10]
Within the broader catalogue, ipamorelin's GHS-R1a-mediated GH/IGF-1 axis activity is mechanistically distinct from the tissue-repair focus of BPC-157 and TB-500, the genomic and matrix biology of GHK-Cu, the mitochondrial metabolic signalling of MOTS-c, the systemic triple hormonal agonism of retatrutide, the intracellular NAD+ axis of 5-Amino-1MQ, and the neuropeptide biology of Selank
Bariatric surgery, typically covered by insurance, is another option
[2] VEGFR2 Activation and Angiogenic Pathways BPC-157 activates vascular endothelial growth factor receptor 2 (VEGFR2), the primary receptor driving angiogenesis in endothelial cells
Ongoing investigations seek to fully characterize its effects and expand its applications in biomedical research